Topical antiandrogens (hair)
Clascoterone vs Pyrilutamide vs RU58841
The table compares the compounds’ key data from their entry pages. Open each compound’s full entry for details. Educational content, not medical advice.
Clascoterone | Pyrilutamide | RU58841 | |
|---|---|---|---|
| What it is | Prescription skin treatment for acne that blocks the action of male hormones locally; against hair loss it is still being tested. | Experimental scalp compound for hair loss (KX-826); not proven in humans and not approved anywhere. | Experimental hair loss compound studied only in animals; unproven in humans and not approved as a medicine. |
| Development code / name | CB-03-01 · cortexolone 17α-propionate | — | — |
| Status | Acne: FDA-approved (Winlevi) · Hair (AGA): phase 3 investigational | Clinical trials (phase 2/3, hair loss); not approved anywhere | Experimental; never approved; no completed human trial |
| Mechanism of actionMechanism of actionThe molecular pathway by which a compound acts in the body (e.g. which receptor or enzyme it binds). | Topical androgen-receptor antagonist (local anti-DHT) | Topical androgen-receptor antagonist (local anti-DHT) | Nonsteroidal topical androgen-receptor antagonist (local anti-DHT) |
| Strengths | 1% cream (acne) · 5-7.5% solution (investigational AGA) | — | — |
| OnsetOnsetThe time from dosing until a measurable effect appears. | 4-12 weeks (acne); hair: months, during phase 3 | — | — |
| Development code | — | KX-826 (Kintor Pharmaceutical) | — |
| Form studied | — | Topical solution (e.g. 0.5% / 1.0%, 1-2x daily) | — |
| Evidence | — | Early/mid-phase; published efficacy still lacking | Only animal studies and personal anecdotes; no human data |
| Other code | — | — | PSK-3841 · RU-58841 (Roussel-Uclaf) |
| Access | — | — | Not available as a drug; only unverified grey market |
| Full entry | Open → | Open → | Open → |
What it is
ClascoteronePrescription skin treatment for acne that blocks the action of male hormones locally; against hair loss it is still being tested.
PyrilutamideExperimental scalp compound for hair loss (KX-826); not proven in humans and not approved anywhere.
RU58841Experimental hair loss compound studied only in animals; unproven in humans and not approved as a medicine.
Development code / name
ClascoteroneCB-03-01 · cortexolone 17α-propionate
Pyrilutamide—
RU58841—
Status
ClascoteroneAcne: FDA-approved (Winlevi) · Hair (AGA): phase 3 investigational
PyrilutamideClinical trials (phase 2/3, hair loss); not approved anywhere
RU58841Experimental; never approved; no completed human trial
Mechanism of actionMechanism of actionThe molecular pathway by which a compound acts in the body (e.g. which receptor or enzyme it binds).
ClascoteroneTopical androgen-receptor antagonist (local anti-DHT)
PyrilutamideTopical androgen-receptor antagonist (local anti-DHT)
RU58841Nonsteroidal topical androgen-receptor antagonist (local anti-DHT)
Strengths
Clascoterone1% cream (acne) · 5-7.5% solution (investigational AGA)
Pyrilutamide—
RU58841—
OnsetOnsetThe time from dosing until a measurable effect appears.
Clascoterone4-12 weeks (acne); hair: months, during phase 3
Pyrilutamide—
RU58841—
Development code
Clascoterone—
PyrilutamideKX-826 (Kintor Pharmaceutical)
RU58841—
Form studied
Clascoterone—
PyrilutamideTopical solution (e.g. 0.5% / 1.0%, 1-2x daily)
RU58841—
Evidence
Clascoterone—
PyrilutamideEarly/mid-phase; published efficacy still lacking
RU58841Only animal studies and personal anecdotes; no human data
Other code
Clascoterone—
Pyrilutamide—
RU58841PSK-3841 · RU-58841 (Roussel-Uclaf)
Access
Clascoterone—
Pyrilutamide—
RU58841Not available as a drug; only unverified grey market

